Joined in 2023 
82 
63 About this deal
Shamoon H, Fleischer N, Engl S, Al E (1993) The Effect Of Intensive Treatment Of Diabetes On The Development And Progression Of Long-Term Complications In Insulin-Dependent Diabetes Mellitus. The New England Journal Of Medicine 329: 977–986. Funding: Funding was provided by JDRF (Grant Number 17-2008-715) and the Canadian Diabetes Association (Grant Number OG-3-10-3123-BP). Point-of-care device equipment was provided by Neurometrix Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. SEPTEMBER 4, 2024 - JUNE 6, 2025 Tampere, Finland. Level 2: Sensorimotor Psychotherapy for Developmental & Relational Injury Anti-inflammatory microglia/macrophages are promoted early by red light treatment following T10 hemicontusion spinal cord injury. a– d Total activated microglia/macrophages (ED1 +) per mm 2 contralateral ( a) and ipsilateral ( b) to the injury and example images from SCI ( c) and SCI+670 ( d) groups. e– h M1 (pro-inflammatory) microglia/macrophages (CD80 +ED1 + double labelled) expressed as a proportion of total ED1 + cells contralateral ( e) and ipsilateral ( f) to the injury and example images from SCI ( g) and SCI+670 ( h) groups. i– l: M2 (anti-inflammatory) microglia/macrophages (Arginase1 +ED1 + double labelled) expressed as a proportion of total ED1 + cells contralateral ( i) and ipsilateral ( j) to the injury and example images from SCI ( k) and SCI+670 ( l) groups. All example images are taken from the injury zone of the dorsal horn at 7days post-injury. Schematic cross section of spinal cord ( bottom) indicates location of injury ( dark grey penumbra) and region of quantification ( light grey region). Scale bars: 50μm. * p<0.05 (linear mixed model); ** p<0.01, *** p<0.001 (Student’s t test); † p<0.05, †† p<0.01, ††† p<0.001 (Wilcoxon rank-sum) MARCH 24, 2023 - FEBRUARY 4, 2024 Eastern Time Zone. Level 2: Psychotherapie Sensorimotrice pour le traitement des blessures developpementales
Finding, testing and demonstrating efficacy of new treatments for stroke recovery is a multifaceted challenge. We believe that to advance the field, neurorehabilitation trials need a conceptually rigorous starting framework. An essential first step is to agree on definitions of sensorimotor recovery and on measures consistent with these definitions. Such standardization would allow pooling of participant data across studies and institutions aiding meta-analyses of completed trials, more detailed exploration of recovery profiles of our patients and the generation of new hypotheses. Here, we present the results of a consensus meeting about measurement standards and patient characteristics that we suggest should be collected in all future stroke recovery trials. Recommendations are made considering time post stroke and are aligned with the international classification of functioning and disability. A strong case is made for addition of kinematic and kinetic movement quantification. Further work is being undertaken by our group to form consensus on clinical predictors and pre-stroke clinical data that should be collected, as well as recommendations for additional outcome measurement tools. To improve stroke recovery trials, we urge the research community to consider adopting our recommendations in their trial design. NOVEMBER 17, 2023 - SEPTEMBER 15, 2024 Mountain Time Zone. Level 2: Sensorimotor Psychotherapy for Developmental & Relational Injury - Online Nursing, Midwifery and Allied Health Professions (NMAHP) Research Unit, Glasgow Caledonian University, UK, and Institutes of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.In spite of the systematic overestimation observed with SNCV, the device was able to qualitatively identify abnormality in standard NCS parameters and the presence or absence of DSP extremely well. As determined by ROC curve analysis, we found optimal thresholds of ≤6 µV and ≤48 m/s had excellent operating characteristics for the identification of age- and height-adjusted abnormality in the SNAP and SNCV measured by standard NCS. Although the magnitude of the SNAP threshold was in agreement with our laboratory’s standard NCS lower limit of amplitude potential, the value for SNCV exceeded our laboratory’s value by approximately 6 m/s to 8 m/s, depending on subject’s age and height. [23] However, these threshold values are consistent with established lower limits of the point-of-care device’s nerve conduction values found in an independent study. [18] In addition, we determined that a simple protocol in which abnormality in point-of-care SNAP, SNCV, or both was associated with high sensitivity (95%) and acceptable specificity (71%) for identification of DSP. These operating characteristics are consistent with the view that this device could be used to identify DSP with acceptable levels of accuracy in clinical research settings. MARCH 18, 2023 - DECEMBER 2, 2023 Portland, OR. Level 1: Sensorimotor Psychotherapy for Trauma Themes - Hybrid Esperanza H, Camargo D, Delgado D, Salvini T (2009) Reliability Of Superficial Peroneal, Sural, And Medial Plantar Nerve Conduction Studies: Analysis Of Statistical Methods. Journal Of Clinical Neurophysiology 26: 372–379.
JUNE 29, 2023 - FEBRUARY 14, 2024 Italy (Online). Level 1: Psicoterapia Sensoriomotoria per il trattamento del Trauma - (online) It is thought that SP strengthens instinctual capacities for survival and assists clients to re-instate or develop resources which were unavailable or missing at the time the trauma or wounding occurred. Once resources are developed and in place, the traumatic event can be processed with the aid of resources.
Our Principles
Perkins B, Orszag A, Grewal J, Ng E, Ngo M, et al. (2008) Multi-Stie Testing With A Point-Of-Care Nerve Conduction Device Can Be Used In An Algorithm To Diagnose Diabetic Sensorimotor Polyneuropathy. Diabetes Care 31: 522–524. Departments of Neurology, Neuroscience, and Physical Medicine & Rehabilitation, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. We examined a cohort of type 1 and 2 diabetes subjects with a broad spectrum of nerve injury, of which 22(50%) had DSP, to assess the performance of a novel point-of-care nerve conduction device in the identification of DSP. The device demonstrated excellent intrarater and interrater reproducibility, acceptable accuracy, and good diagnostic validity for the identification of DSP defined electrophysiologically. The level of reproducibility of the point-of-care device appeared to be comparable to reproducibility measures from standard NCS. [30] However, while quantitative accuracy was excellent for SNAP, we observe a systematic overestimation of SNCV by the point-of-care device. From this measurement bias, we determined that adjustment of threshold values is required – either automatically within the programming of the device or in the published normative values for the device - to adequately reflect those of standard NCS. Boulton A, Freeman R, Vinik A, Malik R, Arezzo J, et al. (2005) Diabetic Neuropathies: A Statement By The American Diabetes Association. Diabetes Care 28: 956–962.
Great Deal 
New Comment